Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01877382
Title A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Daiichi Sankyo Inc.
Indications

lymphoma

Advanced Solid Tumor

Therapies

Milademetan Tosylate

Age Groups: adult
Covered Countries USA


No variant requirements are available.